Advertisement

Picornavirus Entry

  • Jeffrey M. BergelsonEmail author
  • Carolyn B. Coyne
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 790)

Abstract

The essential event in picornavirus entry is the delivery of the RNA genome to the cytoplasm of a target cell, where replication occurs. In the past several years progress has been made in understanding the structural changes in the virion important for uncoating and RNA release. In addition, for several viruses the endocytic mechanisms responsible for internalization have been identified, as have the cellular sites at which uncoating occurs. It has become clear that entry is not a passive process, and that viruses initiate specific signals required for entry. And we have begun to recognize that for a given virus, there may be multiple routes of entry, depending on the particular target cell and the receptors available on that cell.

Keywords

Heparan Sulfate Human Brain Microvascular Endothelial Cell Human Rhinovirus Decay Accelerate Factor Endosomal Acidification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 1985; 229:1358–1365.PubMedCrossRefGoogle Scholar
  2. 2.
    Rossmann MG, Arnold E, Erickson JW et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985; 317:145–153.PubMedCrossRefGoogle Scholar
  3. 3.
    Acharya R, Fry E, Stuart D et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 1989; 337:709–716.PubMedCrossRefGoogle Scholar
  4. 4.
    Chapman MS, Minor I, Rossmann MG et al. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol 1991; 217:455–463.PubMedCrossRefGoogle Scholar
  5. 5.
    Fox MP, Otto MJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother 1986; 30:110–116.PubMedCrossRefGoogle Scholar
  6. 6.
    Grant RA, Hiremath CN, Filman DJ et al. Structures of poliovirus complexes with anti-viral drugs:implications for viral stability and drug design. Curr Biol 1994; 4:784–797.PubMedCrossRefGoogle Scholar
  7. 7.
    Rogers JM, Diana GD, McKinlay MA. Pleconaril. A broad spectrum antipicornaviral agent. Adv Exp Med Biol 1999;458:69–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Li Q, Yafal AG, Lee YM et al. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 1994; 68:3965–3970.PubMedGoogle Scholar
  9. 9.
    Lewis JK, Bothner B, Smith TJ et al. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci USA 1998; 95:6774–6778.PubMedCrossRefGoogle Scholar
  10. 10.
    Olson NH, Kolatkar PR, Oliveria MA et al. Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci USA 1993; 90:507–511.PubMedCrossRefGoogle Scholar
  11. 11.
    Belnap DM, McDermott Jr BM, Filman DJ et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci USA 2000; 97:73–78.PubMedCrossRefGoogle Scholar
  12. 12.
    He Y, Bowman VD, Mueller S et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 2000; 97:79–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Xing L, Tjarnlund K, Lindqvist B et al. Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J 2000; 19:1207–1216.PubMedCrossRefGoogle Scholar
  14. 14.
    He Y, Chipman PR, Howitt J et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol 2001; 8:874–878.PubMedCrossRefGoogle Scholar
  15. 15.
    Casasnovas JM, Springer TA. Kinetics and thermodynamics of virus binding to receptor: studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance. J Biol Chem 1995; 270:13216–13224.PubMedCrossRefGoogle Scholar
  16. 16.
    McDermott Jr BM, Rux AH, Eisenberg RJ et al. Two distinct binding affinities of poliovirus for its cellular receptor. J Biol Chem 2000; 275:23089–23096.PubMedCrossRefGoogle Scholar
  17. 17.
    Kolatkar PR, Bella J, Olson NH et al. Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 1999; 18:6249–6259.PubMedCrossRefGoogle Scholar
  18. 18.
    He Y, Lin F, Chipman PR et al. Structure of decay-accelerating factor bound to echovirus 7:a virus-receptor complex. Proc Natl Acad Sci USA 2002; 99:10325–10329.PubMedCrossRefGoogle Scholar
  19. 19.
    Pettigrew DM, Williams DT, Kerrigan D et al. Structural and functional insights into the interaction of echoviruses and decay-accelerating factor. J Biol Chem 2006; 281:5169–5177.PubMedCrossRefGoogle Scholar
  20. 20.
    Powell RM, Ward T, Evans DJ et al. Interactionbetween echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J Virology 1997; 71:9306–9312.PubMedGoogle Scholar
  21. 21.
    Milstone A, Petrella J, Sanchez M et al. Interaction with coxsackievirus and adenovirus receptor (CAR), but not with decay accelerating factor (DAF), induces A particle formation in a DAF-binding coxsackievirus B3 isolate. J Virol 2005; 79:655–660.PubMedCrossRefGoogle Scholar
  22. 22.
    Crowell RL, Philipson L. Specific alterations of coxsackievirus B3 eluted from HeLa cells. J Virology 1971; 8:509–515.PubMedGoogle Scholar
  23. 23.
    Lonberg-Holm K, Korant BD. Early interaction of rhinoviruses with host cells. J Virol 1972; 9:29–40.PubMedGoogle Scholar
  24. 24.
    De Sena J, Mandel B. Studies on the in vitro uncoating of poliovirus. II. Characteristics of the membrane-modified particle. Virology 1977; 78:554–566.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenwirth B, Eggers HJ. Early processes of echovirus 12-infection: elution, penetration, and uncoating underthe influence of rhodanine. Virology 1979; 97:241–255.PubMedCrossRefGoogle Scholar
  26. 26.
    Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virology 1990; 64:1934–1945.PubMedGoogle Scholar
  27. 27.
    McSharry JJ, Caliguiri LA, Eggars HJ. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 1979; 97:307–315.PubMedCrossRefGoogle Scholar
  28. 28.
    Curry S, Chow M, Hogle JM. The poliovirus 135S particle is infectious. Journal of Virology 1996; 70:7125–7131.PubMedGoogle Scholar
  29. 29.
    Huang Y, Hogle JM, Chow M. Is the 135S poliovirus particle an intermediate during cell entry? J Virology 2000; 74:8757–8761.PubMedCrossRefGoogle Scholar
  30. 30.
    Dove AW, Racaniello VR. Cold-adapted poliovirus mutants bypass a postentry replication block. J Virology 1997; 71:4728–4735.PubMedGoogle Scholar
  31. 31.
    Tosteson MT, Chow M. Characterization ofthe ion channels formed by poliovirus inplanar lipid membranes. J Virol 1997; 71:507–511.PubMedGoogle Scholar
  32. 32.
    Tosteson MT, Wang H, Naumov A et al. Poliovirus binding to its receptor in lipid bilayers results in particle-specific, temperaturesensitive channels. J Gen Virol 2004; 85:1581–1589.PubMedCrossRefGoogle Scholar
  33. 33.
    Danthi P, Tosteson M, Li QH et al. Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus. J Virol 2003; 77:5266–5274.PubMedCrossRefGoogle Scholar
  34. 34.
    Belnap DM, Filman DJ, Trus BL et al. Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus. J Virol 2000; 74:1342–1354.PubMedCrossRefGoogle Scholar
  35. 35.
    Bubeck D, Filman DJ, Cheng N et al. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 2005; 79:7745–7755.PubMedCrossRefGoogle Scholar
  36. 36.
    Lonberg-Holm K, Noble-Harvey J. Comparison of in vitro and cell-mediated alteration of a human Rhinovirus and its inhibition by sodium dodecyl sulfate. J Virol 1973; 12:819–826.PubMedGoogle Scholar
  37. 37.
    Xing L, Casasnovas JM, Cheng RH. Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptor-mediated virus uncoating. J Virol 2003; 77:6101–6107.PubMedCrossRefGoogle Scholar
  38. 38.
    Hewat EA, Neumann E, Blaas D. The concerted conformational changes during human rhinovirus 2 uncoating. Mol Cell 2002; 10:317–326.PubMedCrossRefGoogle Scholar
  39. 39.
    Hewat EA, Blaas D. Cryoelectron microscopy analysis of the structural changes associated with human rhinovirus type 14 uncoating. J Virol 2004; 78:2935–2942.PubMedCrossRefGoogle Scholar
  40. 40.
    Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422:37–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Marsh M, Helenius A. Virus entry: open sesame. Cell 2006; 124:729–740.PubMedCrossRefGoogle Scholar
  42. 42.
    Pelkmans L, Burli T, Zerial M et al. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 2004; 118:767–780.PubMedCrossRefGoogle Scholar
  43. 43.
    Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol 2006; 8:46–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Yafal A, Kaplan G, Racaniello V et al. Characterization of poliovirus conformational alteration mediated by soluble cell receptors. Virology 1993; 197:501–505.CrossRefGoogle Scholar
  45. 45.
    Hoover-Litty H, Greve JM. Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in the virion. J Virology 1993; 67:390–397.PubMedGoogle Scholar
  46. 46.
    Zeichhardt H, Wetz K, Willingmann P et al. Entry of poliovirus type 1 and Mouse Elberfeld (ME) virus into HEp-2. Cells: Receptor-mediated endocytosis and endosomal or lysosomal uncoating. J Virology 1985; 66:483–492.Google Scholar
  47. 47.
    Madshus IH, Olsnes S, Sandvig K. Mechanism of entry into the cytosol of poliovirus type 1: requirement for low pH. J Cell Biol 1984; 98:1194–1200.PubMedCrossRefGoogle Scholar
  48. 48.
    Madshus IH, Olsnes S, Sandvig K. Requirements for poliovirus entry into cells at low pH. EMBO J 1984; 3:1945–1950.PubMedGoogle Scholar
  49. 49.
    Perez L, Carrasco L. Entry of poliovirus into cells does not require a low-pH step. J Virology 1993; 67:4543–4548.PubMedGoogle Scholar
  50. 50.
    DeTulleo L, Kirchhausen T. The clathrin endocytic pathway in viral infection. EMBO J 1998; 17:4585–4593.PubMedCrossRefGoogle Scholar
  51. 51.
    Brandenburg B, Lee LY, Lakadamyali M et al. Imaging poliovirus entry in live cells. PLoS Biology 2007; 5:183–196.CrossRefGoogle Scholar
  52. 52.
    Coyne CB, Kim KS, Bergelson JM. Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2. EMBO Journal 2007; 26:submitted.Google Scholar
  53. 53.
    Brown F, Cartwright B. Dissociation of foot-and-mouth disease virus into its nucleic acid and protein components. Nature 1961; 192:1163–1164.PubMedCrossRefGoogle Scholar
  54. 54.
    Baxt B, Bachrach H. Early interactions of foot-and-mouth disease virus with cultured cells. Virology 1980; 104:42–55.PubMedCrossRefGoogle Scholar
  55. 55.
    O’Donnell V, LaRocco M, Duque H et al. Analysis of foot-and-mouth disease virus internalization events in cultured cells. J Virol 2005; 79:8506–8518.CrossRefGoogle Scholar
  56. 56.
    Berryman S, Clark S, Monaghan P et al. Early events in integrin alphavbeta6-mediated cell entry of foot-and-mouth disease virus. J Virol 2005; 79:8519–8534.PubMedCrossRefGoogle Scholar
  57. 57.
    Mason P, Baxt B, Brown F et al. Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor. Virology 1993; 192:568–577.PubMedCrossRefGoogle Scholar
  58. 58.
    Snyers L, Zwickl H, Blaas D. Human rhinovirus type 2 is internalized by clathrin-mediated endocytosis. J Virol 2003; 77:5360–5369.PubMedCrossRefGoogle Scholar
  59. 59.
    Bayer N, Schober D, Huttinger M et al. Inhibition of clathrin-dependent endocytosis has multiple effects on human rhinovirus serotype 2 cell entry. J Biol Chem 2001; 276:3952–3962.PubMedCrossRefGoogle Scholar
  60. 60.
    Brabec M, Baravalle G, Blaas D et al. Conformational changes, plasmamembrane penetration, and infection by human rhinovirus type 2: role of receptors and low pH. J Virol 2003; 77:5370–5377.PubMedCrossRefGoogle Scholar
  61. 61.
    Nurani G, Lindqvist B, Casasnovas JM. Receptor priming of maj or group human rhinoviruses for uncoating and entry at mild low-pH environments. J Virol 2003; 77:11985–11991.PubMedCrossRefGoogle Scholar
  62. 62.
    Khan AG, Pichler J, Rosemann A et al. Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH. J Virol 2007; 81:4625–4632.PubMedCrossRefGoogle Scholar
  63. 63.
    Vlasak M, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J Virol 2005; 79:5963–5970.PubMedCrossRefGoogle Scholar
  64. 64.
    Reischl A, Reithmayer M, Winsauer G et al. Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells. J Virol 2001; 75:9312–9319.PubMedCrossRefGoogle Scholar
  65. 65.
    Brabec M, Schober D, Wagner E et al. Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol 2005; 79:1008–1016.PubMedCrossRefGoogle Scholar
  66. 66.
    Schober D, Kronenberger P, Prchla E et al. Major and minor receptor group human rhinoviruses penetrate from endosomes by different mechanisms. J Virol 1998; 72:1354–1364.PubMedGoogle Scholar
  67. 67.
    Bergelson JM, Shepley MP, Chan BMC et al. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science 1992; 255:1718–1720.PubMedCrossRefGoogle Scholar
  68. 68.
    King SL, Kamata T, Cunningham JA et al. Echovirus 1 interaction with the human very late antigen-2 (integrin α2β1) I domain: identification of two independent virus contact sites distinct from the metal ion-dependent adhesion site. J Biol Chem 1997; 272:28518–28522.PubMedCrossRefGoogle Scholar
  69. 69.
    Xing L, Huhtala M, Pietiainen V et al. Structural and functional analysis of integrin alpha2I domain interaction with echovirus 1. J Biol Chem 2004; 279:11632–11638.PubMedCrossRefGoogle Scholar
  70. 70.
    Pietiainen V, Marjomaki V, Upla P et al. Echovirus 1 endocytosis into caveosomes requires lipid rafts, dynamin II, and signaling events. Mol Biol Cell 2004; 15:4911–4925.PubMedCrossRefGoogle Scholar
  71. 71.
    Upla P, Marjomaki V, Kankaanpaa P et al. Clustering induces a lateral redistribution of alpha 2 beta 1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent internalization. Mol Biol Cell 2004; 15:625–636.PubMedCrossRefGoogle Scholar
  72. 72.
    Marjomaki V, Pietiainen V, Matilainen H et al. Internalization of echovirus 1 in caveolae. J Virol 2002; 76:1856–1865.PubMedCrossRefGoogle Scholar
  73. 73.
    Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275:1320–1323.PubMedCrossRefGoogle Scholar
  74. 74.
    Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci 1997; 94:3352–3356.PubMedCrossRefGoogle Scholar
  75. 75.
    Martino TA, Petric M, Weingartl H et al. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B, and by swine vesicular disease virus. Virology 2000; 271:99–108.PubMedCrossRefGoogle Scholar
  76. 76.
    Bergelson JM, Mohanty JG, Crowell RL et al. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virology 1995; 69:1903–1906.PubMedGoogle Scholar
  77. 77.
    Shafren DR, Bates RC, Agrez MV et al. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virology 1995; 69:3873–3877.PubMedGoogle Scholar
  78. 78.
    Triantafilou K, Triantafilou M. Lipid-raft-dependent Coxsackievirus B4 internalization and rapid targeting to the Golgi. Virology 2004; 326:6–19.PubMedCrossRefGoogle Scholar
  79. 79.
    Chung SK, Kim JY, Kim IB et al. Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells. Virology 2005; 333:31–40.PubMedCrossRefGoogle Scholar
  80. 80.
    Stuart AD, Eustace HE, McKee TA et al. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. J Virol 2002; 76:9307–9322.PubMedCrossRefGoogle Scholar
  81. 81.
    Cohen CJ, Shieh JT-C, Pickles RJ et al. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA 2001; 98:15191–15196.PubMedCrossRefGoogle Scholar
  82. 82.
    Shieh JTC, Bergelson JM. Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells. J Virology 2002; 76:9474–9480.PubMedCrossRefGoogle Scholar
  83. 83.
    Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006; 124:119–131.PubMedCrossRefGoogle Scholar
  84. 84.
    Coyne CB, Shen L, Turner JR et al. Coxsackievirus entry from epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host and Microbe 2007; 2:181–192.PubMedCrossRefGoogle Scholar
  85. 85.
    Bubeck D, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction of a poliovirus-receptor-membrane complex. Nat Struct Mol Biol 2005; 12:615–618.PubMedCrossRefGoogle Scholar
  86. 86.
    Tuthill TJ, Bubeck D, Rowlands DJ et al. Characterization of early steps in the polio virus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles. J Virol 2006; 80:172–180.PubMedCrossRefGoogle Scholar
  87. 87.
    Brandenburg B, Zhuang X. Virus trafficking—learning from single-virus tracking. Nat Rev Microbiol 2007; 5:197–208.PubMedCrossRefGoogle Scholar
  88. 88.
    Pelkmans L, Fava E, Grabner H et al. Genome-wide analysis of human kinases in clathrin-and caveolae/raft-mediated endocytosis. Nature 2005; 436:78–86.PubMedCrossRefGoogle Scholar
  89. 89.
    Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56:855–865.PubMedCrossRefGoogle Scholar
  90. 90.
    Greve JM, Davis G, Meyer AM et al.The major human rhinovirus receptor is ICAM-1. Cell 1989; 56:839–847.PubMedCrossRefGoogle Scholar
  91. 91.
    Staunton DE, Merluzzi VJ, Rothlein R et al. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989; 56:849–853.PubMedCrossRefGoogle Scholar
  92. 92.
    Tomassini JE, Graham D, DeWitt CM et al. cDNA cloning reveals that the maj or group rhino virus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1989; 86:4907–4911.PubMedCrossRefGoogle Scholar
  93. 93.
    Hofer F, Gruenberger M, Kowalski H et al. Members of the low density lipoprotein recepto family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci 1994; 91: 1839–1842.PubMedCrossRefGoogle Scholar
  94. 94.
    Zautner AE, Korner U, Henke A et al. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 2003; 77:10071–10077.PubMedCrossRefGoogle Scholar
  95. 95.
    Bergelson JM, Chan M, Solomon K et al. Decay-accelerating factor, a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sei. USA 1994; 91:6245–6248.CrossRefGoogle Scholar
  96. 96.
    Ward T, Pipkin PA, Clarkson NA et al. Decay accelerating factor (CD55) identified as a receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J 1994; 13: 5070–5074.PubMedGoogle Scholar
  97. 97.
    Goodfellow IG, Sioofy AB, Powell RM et al. Echoviruses bind heparan sulfate at the cell surface. J Virol 2001; 75:4918–4921.PubMedCrossRefGoogle Scholar
  98. 98.
    Shafren DR, Dorahy DJ, Greive SJ et al. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J Virol 1997; 71:785–789.PubMedGoogle Scholar
  99. 99.
    Shafren DR, Dorahy DJ, Ingham RA et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997; 71:4736–4743.PubMedGoogle Scholar
  100. 100.
    Roivainen M, Piirainen L, Hovi T et al. Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor. Virology 1994; 203:357–365.PubMedCrossRefGoogle Scholar
  101. 101.
    Triantafilou K, Fradelizi D, Wilson K et al. GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatability complex class I molecules which mediate virus internalization. J Virol 2002; 76:633–643.PubMedCrossRefGoogle Scholar
  102. 102.
    Yamayoshi S, Yamashita Y, Li J et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009; 15:798–801.PubMedCrossRefGoogle Scholar
  103. 103.
    Nishimura Y, Shimojima M, Tano Y et al. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009; 15:794–797.PubMedCrossRefGoogle Scholar
  104. 104.
    Tan CW, Poh CL, Sam IC, Chan YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 2013; 87:611–620.PubMedCrossRefGoogle Scholar
  105. 105.
    Jackson T, Mould AP, Sheppard D et al. Integrin alphavbetal is a receptor for foot-and-mouth disease virus. J Virol 2002; 76:935–941.PubMedCrossRefGoogle Scholar
  106. 106.
    Berinstein A, Roivainen M, Hovi T et al. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 1995; 69:2664–2666.PubMedGoogle Scholar
  107. 107.
    Jackson T, Clark S, Berryman S et al. Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J Virol 2004; 78:4533–4540.PubMedCrossRefGoogle Scholar
  108. 108.
    Jackson T, Sheppard D, Denyer M et al. The epithelial integrin alphavbeta6 is areceptorfor foot-and-mouth disease virus. J Virol 2000; 74:4949–4956.PubMedCrossRefGoogle Scholar
  109. 109.
    Jackson T, Ellard FM, Ghazaleh RA et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996; 70: 5282–5287.PubMedGoogle Scholar
  110. 110.
    Huber SA. VCAM-1 is a receptor for encephalomyocarditis virus on murine vascular endothelial cells. J Virol 1994; 68:3453–3458.PubMedGoogle Scholar
  111. 111.
    Filman DJ, Syed R, Chow M et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 1989; 8:1567–1579.PubMedGoogle Scholar
  112. 112.
    Yoder JD, Cifuente JO, Pan J et al. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface. J Virol 2012; 86:12571–12581.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2013

Authors and Affiliations

  1. 1.Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Division of Infectious DiseasesChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department Microbiology and Molecular GeneticsUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations